$Corvus Pharmaceuticals(CRVS.US)$But its nice to see when i do agree! Even lower by a buck 7 would still be killer gains! LMAO. ((((((. Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7. )))))
$Corvus Pharmaceuticals(CRVS.US)$Corvus Pharmaceuticals (CRVS) said Tuesday it expects to start a phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis in Q2. Corvus expects to enroll 64 patients who have previously failed at least one therapy and compare four different doses of the drug with placebo for safety and disease severity in the 28-day trial. An initial readout of the trial is possible before the year's end, according to the company.
$Corvus Pharmaceuticals(CRVS.US)$Corvus Pharmaceuticals has received FDA Orphan Drug Designation for its drug candidate soquelitinib for the treatment of T-cell lymphoma. The company expects to begin a Phase 3 registrational study for the product in patients with relapsed peripheral T-cell lymphoma in Q2. The designation provides certain benefits to drug developers, including seven years market exclusivity if the drug is approved.
$Corvus Pharmaceuticals(CRVS.US)$Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma 6 MINUTES AGO, 4:05 PM EST VIA GLOBENEWSWIRE
Jeffrey Arcara's appointment as Chief Business Officer is anticipated to bolster Corvus Pharmaceuticals' ITK programs. His vast industry experience is seen as a valuable asset for the company's future.
Corvus Pharmaceuticals股票讨论区
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
I don’t put much credibility in analysts PT’s because they mis so often! Hehehe
Update
Corvus expects to enroll 64 patients who have previously failed at least one therapy and compare four different doses of the drug with placebo for safety and disease severity in the 28-day trial.
An initial readout of the trial is possible before the year's end, according to the company.
Watching for earnings numbers!
Just in case you missed this in AM last evening?
The company expects to begin a Phase 3 registrational study for the product in patients with relapsed peripheral T-cell lymphoma in Q2.
The designation provides certain benefits to drug developers, including seven years market exclusivity if the drug is approved.
News
6 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
暂无评论